Recent Progress in Stem Cell Research of the Pituitary Gland and Pituitary Adenoma

Toda, Masataro; Tamura, Ryota; Toda, Masahiro

doi:10.3390/endocrines1010006

Cited by 2 publications

(2 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PIT1 (also known as POU1F1), a POU domain-containing transcription factor, is essential for the terminal cell differentiation and gene expression of normal pituitary cells that go on to secrete the neuroendocrine hormones PRL, GH, and TSH [11]. The formation of these normal pituitary cells of the PIT1 lineage is positively regulated by PROP1 and negatively regulated by HESX1 [20].…”

Section: Development Of Normal Pituitary Cells Of the Pit1-lineagementioning

confidence: 99%

Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor Cells

Osorio

Jung

et al. 2022

Cancers

View full text Add to dashboard Cite

The pituitary gland is one of the most cellularly diverse regions of the brain. Recent advancements in transcriptomic biology, such as single-cell RNA sequencing, bring an unprecedented glimpse into the molecular composition of the pituitary, both in its normal physiological state and in disease. Deciphering the normal pituitary transcriptomic signatures provides a better insight into the ontological origin and development of five types of endocrine cells, a process involving complex cascades of transcription factors that are still being established. In parallel with these observations about normal pituitary development, recent transcriptomic findings on pituitary neuroendocrine tumors (PitNETs) demonstrate both preservations and changes in transcription factor expression patterns compared to those seen during gland development. Furthermore, recent studies also identify differentially expressed genes that drive various tumor behaviors, including hormone hypersecretion and tumor aggression. Understanding the comprehensive multiomic profiles of PitNETs is essential in developing molecular profile-based therapies for PitNETs not curable with current treatment modalities and could eventually help align PitNETs with the breakthroughs being made in applying precision medicine to other tumors.

show abstract

Section: Development Of Normal Pituitary Cells Of the Pit1-lineagementioning

confidence: 99%

Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor Cells

Osorio

Jung

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…In general, tumor stem cells are derived from normal tissue specific cells or re-differentiate and/or de-differentiate from progenitor/differentiated cells. Some studies have discussed the relationship between genetic alterations in human pituitary gland stem cells and tumors formed from pituitary adenoma stem cells (PASCs) [ 76 , 77 ]. While stem-like cells are particularly resistant to classical cytotoxic drugs due to the overexpression of drug-extruding pumps and DNA-repairing enzymes [ 77 ], many previous studies demonstrated a higher sensitivity of tumor stem cell subpopulation to metformin [ 78 ], which may lead to the development of a DR approach in PitNETs [ 79 , 80 ].…”

Section: Pituitary Neuroendocrine Tumormentioning

confidence: 99%

Drug Repositioning for Refractory Benign Tumors of the Central Nervous System

Tamura

2023

IJMS

Self Cite

View full text Add to dashboard Cite

Drug repositioning (DR) is the process of identifying novel therapeutic potentials for already-approved drugs and discovering new therapies for untreated diseases. DR can play an important role in optimizing the pre-clinical process of developing novel drugs by saving time and cost compared with the process of de novo drug discovery. Although the number of publications related to DR has rapidly increased, most therapeutic approaches were reported for malignant tumors. Surgical resection represents the definitive treatment for benign tumors of the central nervous system (BTCNS). However, treatment options remain limited for surgery-, chemotherapy- and radiation-refractory BTCNS, as well as malignant tumors. Meningioma, pituitary neuroendocrine tumor (PitNET), and schwannoma are the most common BTCNS. The treatment strategy using DR may be applied for refractory BTCNS, such as Grade 2 meningiomas, neurofibromatosis type 2-related schwannomatosis, and PitNETs with cavernous sinus invasion. In the setting of BTCNS, stable disease can provide significant benefit to the patient. DR may provide a longer duration of survival without disease progression for patients with refractory BTCNS. This article reviews the utility of DR for refractory BTCNS.

show abstract

Recent Progress in Stem Cell Research of the Pituitary Gland and Pituitary Adenoma

Cited by 2 publications

References 59 publications

Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor Cells

Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor Cells

Drug Repositioning for Refractory Benign Tumors of the Central Nervous System

Contact Info

Product

Resources

About